Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CEO Sells 1,938 Shares of Stock

Posted by George Bondi on May 18th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CEO Jason Coloma sold 1,938 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $26.00, for a total value of $50,388.00. Following the sale, the chief executive officer directly owned 31,001 shares in the company, valued at $806,026. This represents a 5.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Down 4.1%

Shares of Maze Therapeutics stock traded down $1.06 during trading hours on Monday, reaching $24.50. 596,266 shares of the company were exchanged, compared to its average volume of 727,496. Maze Therapeutics, Inc. has a 1 year low of $9.15 and a 1 year high of $53.65. The stock’s fifty day moving average is $33.41 and its 200 day moving average is $37.97. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The firm has a market cap of $1.36 billion, a PE ratio of -9.68 and a beta of 2.50.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. As a group, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.63 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics in the 4th quarter valued at $39,000. Ameritas Investment Partners Inc. grew its stake in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics during the 4th quarter valued at $43,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares during the period.

Wall Street Analyst Weigh In

Several research firms have issued reports on MAZE. Truist Financial decreased their price objective on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, April 14th. JPMorgan Chase & Co. upped their price objective on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 31st. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, March 25th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $66.00.

Get Our Latest Stock Analysis on Maze Therapeutics

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.